Country: United States
Language: English
Source: NLM (National Library of Medicine)
lanreotide acetate (UNII: IEU56G3J9C) (lanreotide - UNII:0G3DE8943Y)
Beaufour Ipsen Pharma SAS
lanreotide acetate
60 mg in 0.2 mL
PRESCRIPTION DRUG
SOMATULINE DEPOT- LANREOTIDE ACETATE INJECTION BEAUFOUR IPSEN PHARMA SAS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION INDICATIONS AND USAGE Somatuline Depot (lanreotide) Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy (1) DOSAGE AND ADMINISTRATION Dose range of 60 mg to 120 mg every 4 weeks (2) Recommended dose is 90 mg every 4 weeks for 3 months. Adjust thereafter based on GH and/or IGF-1 levels (2) Renal and Hepatic Impairment: Initial dose is 60 mg every 4 weeks for 3 months in moderate and severe renal or hepatic impairment. Adjust thereafter based on GH and/or IGF-1 levels. (2, 12.3) Injected in the superior external quadrant of the buttock Injection site should be alternated (2) Store at 2-8°C (36-46 °F) in the original package (16.2) DOSAGE FORMS AND STRENGTHS Single use syringe: 60, 90 and 120 mg (3) CONTRAINDICATIONS None (5) WARNINGS AND PRECAUTIONS Gallbladder: Gallstones may occur; consider periodic monitoring (5.1) Glucose Metabolism: Hypo- and/or hyperglycemia may occur. Glucose monitoring is recommended and anti-diabetic treatment adjusted accordingly (5.2) Cardiac Function: Decrease in heart rate may occur. Use with caution in at-risk patients (5.3) ADVERSE REACTIONS Most common adverse reactions are diarrhea, cholelithiasis, abdominal pain, nausea and injection site reactions (6) DRUG INTERACTIONS Hypoglycemia agents: Hypo- and/or hyperglycemia may occur. Glucose monitoring is recommended and anti-diabetic treatment adjusted accordingly (7.1) Cyclosporine: Somatuline may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted (7.2) Drugs affecting heart rate: Somatuline may decrease heart rate. Dose adjustment of coadministered drugs that decrease heart rate may be necessary (7.3) USE IN SPECIFIC POPULATIONS Renal Impairment: Start dose is 60 mg in moderate and severe renal impairment (2, 8.6, 12.3) Hepatic Impairment: Read the complete document